中文摘要：

目的研究视网膜分支静脉阻塞继发黄斑水肿（BRVO-ME）患者应用雷珠单抗玻璃体腔注射联合格栅样视网膜激光光凝术（GLP）治疗的临床效果。方法选取135例（135眼）BRVO-ME临床资料,随机分为单纯药物组（n=45）、单纯激光组（n=45）、联合治疗组（n=45）,单纯药物组仅应用雷珠单抗玻璃体腔注射,单纯激光组仅应用GLP治疗,联合治疗组先予雷珠单抗玻璃体腔注射,间隔1周后应用GLP治疗。结果三组治疗3个月后最佳矫正视力（BCVA）水平对比,较治疗前差异有统计学意义（P〈0.05）,且联合治疗组治疗1、2、3个月后BCVA水平较同期单纯药物组、单纯激光组差异有统计学意义（P〈0.05）。三组治疗3个月后黄斑中心凹视网膜厚度（CMT）水平对比,均较治疗前差异有统计学意义（P〈0.05）,且联合治疗1、2、3个月后CMT水平较同期单纯药物组、单纯激光组差异均有统计学意义（P〈0.05）。结论玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME较单纯药物和单纯激光治疗,降低黄斑中心凹视网膜厚度、改善黄斑水肿、提高视力效果更明显,复发率更低,安全有效。

英文摘要：

Objective To explore the clinical efficacy of branch retinal vein occlusion secondary macular edema（ BRVO-ME） treated with Ranibizumab intravitreal injection combined with grille laser photocoagulation（ GLP）. Methods A total of 135（ 135 eyes） BRVO-ME cases were divided into 3 groups： simple drug group（ n = 45）,simple laser group（ n = 45）,and combined treatment group（ n = 45）. The simple drug group received Ranibizumab intravitreal injection only. The simple laser group received GLP only. The combined treatment group received Ranibizumab intravitreal injection first,and then GLP 1 week after. The best corrected visual acuity（ BCVA）,central macular thickness（ CMT）,and intraocular pressure（ IOP） of the 3 groups were observed. Results Three months after treatment,BCVA and CMT of all groups were significantly different（ P〈0. 05）. The combined treatment group had significantly lower BCVA and CMT than the other 2 groups in postoperative month 1,2 and 3（ P〈0. 05）. During the treatment,no increased IOP was observed（ P〈0. 05）. No postoperative infection,vitreous hemorrhage,bacterial endophthalmitis or other adverse reactions occurred. Conclusion Ranibizumab intravitreal injection combined with GLP is safe and effective in the treatment of BRVO-ME,which can reduce the CMT,relieve macular edema,and improve visual acuity.